Stratified neutrophil-to-lymphocyte ratio accurately predict mortality risk in hepatocellular carcinoma patients following curative liver resection

Oncotarget

Volumn 7, Issue 5, 2016, Pages 5429-5439

  Huang, Gui Qian ^a,b   Zhu, Gui Qi ^a,b   Liu, Yan Long ^b   Wang, Li Ren ^a,b   Braddock, Martin ^c   Zheng, Ming Hua ^a,b   Zhou, Meng Tao ^b  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Curative liver resection; Hepatocellular carcinoma; Neutrophil to lymphocyte ratio; Overall survival

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CHILD PUGH SCORE; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MICROVASCULAR INVASION; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; SURGICAL MORTALITY; TUMOR INVASION; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; COHORT ANALYSIS; FOLLOW UP; LIVER NEOPLASMS; LYMPHOCYTE; MIDDLE AGED; MORTALITY; NEUTROPHIL; PATHOLOGY; PROGNOSIS; RISK FACTOR; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPHILS; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; YOUNG ADULT;

EID: 84958088005     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6707     Document Type: Article

References (42)

1. Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, Heathcote J, Piratsivuth T, Kew M, Otegbayo JA, Zheng SS, Sarin S, Hamid SS, et al. Hepatocellular carcinoma (HCC): a global perspective. Journal of clinical gastroenterology. 2010;44:239-245.
2. Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA: a cancer journal for clinicians. 2012;62:394-399.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011;61:69-90.
4. Du ZG, Wei YG, Chen KF, Li B. Risk factors associated with early and late recurrence after curative resection of hepatocellular carcinoma: a single institution's experience with 398 consecutive patients. Hepatobiliary & pancreatic diseases international: HBPD INT. 2014;13:153-161.
5. Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary & pancreatic diseases international: HBPD INT. 2008;7:237-257.
6. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Annals of surgery. 2002;235:373-382.
7. Kim do Y, Han KH. Epidemiology and surveillance of hepatocellular carcinoma. Liver cancer. 2012;1:2-14.
8. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519-524.
9. Wei K, Wang M, Zhang W, Mu H, Song TQ. Neutrophillymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib. Medical oncology (Northwood, London, England). 2014;31:969.
10. Tan CK, Law NM, Ng HS, Machin D. Simple clinical prognostic model for hepatocellular carcinoma in developing countries and its validation. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2003;21:2294-2298.
11. Schoniger-Hekele M, Muller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A. Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut. 2001;48:103-109.
12. Motomura T, Shirabe K, Mano Y, Muto J, Toshima T, Umemoto Y, Fukuhara T, Uchiyama H, Ikegami T, Yoshizumi T, Soejima Y, Maehara Y. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. Journal of hepatology. 2013;58:58-64.
13. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.
14. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539-545.
15. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxidedependent mechanism. Cancer research. 2000;60:184-190.
16. Kim IY, You SH, Kim YW. Neutrophil-lymphocyte ratio predicts pathologic tumor response and survival after preoperative chemoradiation for rectal cancer. BMC surgery. 2014;14:94.
17. Kobayashi N, Usui S, Kikuchi S, Goto Y, Sakai M, Onizuka M, Sato Y. Preoperative lymphocyte count is an independent prognostic factor in node-negative non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2012;75:223-227.
18. Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, Widmann WD. Usefulness of the neutrophilto-lymphocyte ratio in predicting short-and long-term mortality in breast cancer patients. Annals of surgical oncology. 2012;19:217-224.
19. Jung MR, Park YK, Jeong O, Seon JW, Ryu SY, Kim DY, Kim YJ. Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. Journal of surgical oncology. 2011;104:504-510.
20. Halazun KJ, Hardy MA, Rana AA, Woodland DCt, Luyten EJ, Mahadev S, Witkowski P, Siegel AB, Brown RS, Jr., Emond JC. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Annals of surgery. 2009;250:141-151.
21. Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JP, Prasad KR. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World journal of surgery. 2008;32:1757-1762.
22. Spolverato G, Maqsood H, Kim Y, Margonis G, Luo T, Ejaz A, Pawlik TM. Neutrophil-lymphocyte and plateletlymphocyte ratio in patients after resection for hepato-pancreatico-biliary malignancies. Journal of surgical oncology. 2015;111:868-874.
23. Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RI. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. American journal of surgery. 2010;200:197-203.
24. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. Journal of surgical oncology. 2005;91:181-184.
25. Mantovani A, Allavena P, Sica A, Balkwill F. Cancerrelated inflammation. Nature. 2008;454:436-444.
26. Okamura Y, Ashida R, Ito T, Sugiura T, Mori K, Uesaka K. Preoperative neutrophil to lymphocyte ratio and prognostic nutritional index predict overall survival after hepatectomy for hepatocellular carcinoma. World journal of surgery. 2015;39:1501-1509.
27. Gao F, Li X, Geng M, Ye X, Liu H, Liu Y, Wan G, Wang X. Pretreatment neutrophil-lymphocyte ratio: an independent predictor of survival in patients with hepatocellular carcinoma. Medicine. 2015;94:e639.
28. Xu X, Chen W, Zhang L, Miao R, Zhou Y, Wan Y, Dong Y, Liu C. Prognostic significance of neutrophil to lymphocyte ratio in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization. Chinese medical journal. 2014;127:4204-4209.
29. Xiao WK, Chen D, Li SQ, Fu SJ, Peng BG, Liang LJ. Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis. BMC cancer. 2014;14:117.
30. Mukherjee M, Sahasrabuddhe MB. Effect of operation on peripheral lymphocyte counts and production of adenosine triphosphate (ATP) in cancer patients. Journal of surgical oncology. 1982;20:1-8.
31. Liao W, Zhang J, Zhu Q, Qin L, Yao W, Lei B, Shi W, Yuan S, Tahir SA, Jin J, He S. Preoperative Neutrophilto-Lymphocyte Ratio as a New Prognostic Marker in Hepatocellular Carcinoma after Curative Resection. Translational oncology. 2014;7:248-255.
32. Zhao QT, Yang Y, Xu S, Zhang XP, Wang HE, Zhang H, Wang ZK, Yuan Z, Duan GC. Prognostic role of neutrophil to lymphocyte ratio in lung cancers: a meta-analysis including 7, 054 patients. OncoTargets and therapy. 2015;8:2731-2738.
33. Price TH, Chatta GS, Dale DC. Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood. 1996;88:335-340.
34. Ulich TR, del Castillo J, Watson LR, Yin SM, Garnick MB. In vivo hematologic effects of recombinant human macrophage colony-stimulating factor. Blood. 1990;75:846-850.
35. Lord BI, Bronchud MH, Owens S, Chang J, Howell A, Souza L, Dexter TM. The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proceedings of the National Academy of Sciences of the United States of America. 1989;86:9499-9503.
36. Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis. 2003;6:283-287.
37. Blank S, Wang Q, Fiel MI, Luan W, Kim KW, Kadri H, Mandeli J, Hiotis SP. Assessing prognostic significance of preoperative alpha-fetoprotein in hepatitis B-associated hepatocellular carcinoma: normal is not the new normal. Annals of surgical oncology. 2014;21:986-994.
38. Zhu GQ, Shi KQ, Yu HJ, He SY, Braddock M, Zhou MT, Chen YP, Zheng MH. Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis. Oncotarget. 2015;6:18151-18161. doi:10.18632/oncotarget.4098.
39. Zhang JB, Zhang B, Guo L, Lin ZH, Li XQ, Guo K, Sun HC, Ye QH. Peritumoral Cbl is a strong independent prognostic marker after curative resection of hepatocellular carcinoma. Oncotarget. 2015;6:40223-40234. doi: 10.18632/oncotarget.5540.
40. Zhuang L, Xu L, Wang P, Jiang Y, Yong P, Zhang C, Zhang H, Meng Z, Yang P. Na+/K+-ATPase alpha1 subunit, a novel therapeutic target for hepatocellular carcinoma. Oncotarget. 2015;6:28183-28193. doi:10.18632/oncotarget.4726.
41. Vauthey JN, Lauwers GY, Esnaola NF, Do KA, Belghiti J, Mirza N, Curley SA, Ellis LM, Regimbeau JM, Rashid A, Cleary KR, Nagorney DM. Simplified staging for hepatocellular carcinoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2002;20:1527-1536.
42. Huang S, Huang GQ, Zhu GQ, Liu WY, You J, Shi KQ, Wang XB, Che HY, Chen GL, Fang JF, Zhou Y, Zhou MT, Chen YP, et al. Establishment and Validation of SSCLIP Scoring System to Estimate Survival in Hepatocellular Carcinoma Patients Who Received Curative Liver Resection. PLoS One. 2015;10:e0129000.